LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells

    Dennis C. Copertino Jr. / Carissa S. Holmberg / Jared Weiler / Adam R. Ward / J. Natalie Howard / Callie Levinger / Alina P.S. Pang / Michael J. Corley / Friederike Dündar / Paul Zumbo / Doron Betel / Rajesh T. Gandhi / Deborah K. McMahon / Ronald J. Bosch / Noemi Linden / Bernard J. Macatangay / Joshua C. Cyktor / Joseph J. Eron / John W. Mellors /
    Colin Kovacs / Erika Benko / Alberto Bosque / R. Brad Jones

    JCI Insight, Vol 8, Iss

    2023  Volume 18

    Abstract: IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydroxy- ... ...

    Abstract IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydroxy-1,2,3-benzotriazin-4(3H)-one (HODHBt) enhances IL-15–mediated latency reversal and NK cell function by increasing STAT5 activation. We hypothesized that HODHBt would also synergize with IL-15, via STAT5, to directly enhance HIV-specific cytotoxic T cell responses. We showed that ex vivo IL-15 + HODHBt treatment markedly enhanced HIV-specific granzyme B–releasing T cell responses in PBMCs from antiretroviral therapy–suppressed (ART-suppressed) donors. We also observed upregulation of antigen processing and presentation in CD4+ T cells and increased surface MHC-I. In ex vivo PBMCs, IL-15 + HODHBt was sufficient to reduce intact proviruses in 1 of 3 ART-suppressed donors. Our findings reveal the potential for second-generation IL-15 studies incorporating HODHBt-like therapeutics. Iterative studies layering on additional latency reversal or other agents are needed to achieve consistent ex vivo reservoir reductions.
    Keywords AIDS/HIV ; Immunology ; Medicine ; R
    Subject code 570
    Language English
    Publishing date 2023-09-01T00:00:00Z
    Publisher American Society for Clinical investigation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Dynamics of HIV-specific T cells on long-term ART differ by antigen recognised and by sex

    Eva M. Stevenson / Adam R. Ward / Thomas R. Dilling / John K. Bui / John Mellors / Rajesh Gandhi / Deborah McMahon / Joseph Eron / Ronald Bosch / Christina Lalama / Joshua Cyktor / Brad Jones

    Journal of Virus Eradication, Vol 5, Iss , Pp 32- (2019)

    2019  

    Keywords Microbiology ; QR1-502 ; Public aspects of medicine ; RA1-1270
    Language English
    Publishing date 2019-12-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy

    Eva M. Stevenson / Adam R. Ward / Ronald Truong / Allison S. Thomas / Szu-Han Huang / Thomas R. Dilling / Sandra Terry / John K. Bui / Talia M. Mota / Ali Danesh / Guinevere Q. Lee / Andrea Gramatica / Pragya Khadka / Winiffer D. Conce Alberto / Rajesh T. Gandhi / Deborah K. McMahon / Christina M. Lalama / Ronald J. Bosch / Bernard Macatangay /
    Joshua C. Cyktor / Joseph J. Eron / John W. Mellors / R. Brad Jones / for the AIDS Clinical Trials Group A5321 Team

    JCI Insight, Vol 6, Iss

    2021  Volume 3

    Abstract: Antiretroviral therapies (ARTs) abrogate HIV replication; however, infection persists as long-lived reservoirs of infected cells with integrated proviruses, which reseed replication if ART is interrupted. A central tenet of our current understanding of ... ...

    Abstract Antiretroviral therapies (ARTs) abrogate HIV replication; however, infection persists as long-lived reservoirs of infected cells with integrated proviruses, which reseed replication if ART is interrupted. A central tenet of our current understanding of this persistence is that infected cells are shielded from immune recognition and elimination through a lack of antigen expression from proviruses. Efforts to cure HIV infection have therefore focused on reactivating latent proviruses to enable immune-mediated clearance, but these have yet to succeed in reducing viral reservoirs. Here, we revisited the question of whether HIV reservoirs are predominately immunologically silent from a new angle: by querying the dynamics of HIV-specific T cell responses over long-term ART for evidence of ongoing recognition of HIV-infected cells. In longitudinal assessments, we show that the rates of change in persisting HIV Nef-specific responses, but not responses to other HIV gene products, were associated with residual frequencies of infected cells. These Nef-specific responses were highly stable over time and disproportionately exhibited a cytotoxic, effector functional profile, indicative of recent in vivo recognition of HIV antigens. These results indicate substantial visibility of the HIV-infected cells to T cells on stable ART, presenting both opportunities and challenges for the development of therapeutic approaches to curing infection.
    Keywords AIDS/HIV ; Immunology ; Medicine ; R
    Subject code 570
    Language English
    Publishing date 2021-02-01T00:00:00Z
    Publisher American Society for Clinical investigation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top